Zevra Posts $106.5M 2025 Revenue and $83.2M Net Income
Zevra posted Q4 net revenue of $34.1 million, up 31% sequentially, and full-year 2025 net sales of $106.5 million driven by $87.4 million of MIPLYFFA revenue. Zevra swung to $83.2 million net income with $1.40 EPS versus a $105.5 million loss as market access hit 68% and enrolled 52 forms.
1. Financial Results for Q4 and Full Year 2025
Zevra reported Q4 net revenue of $34.1 million, marking a 31% sequential increase, and achieved full-year net sales of $106.5 million. The company delivered net income of $83.2 million, or $1.40 basic EPS, compared with a net loss of $105.5 million in 2024, reflecting improved margins and cost control.
2. MIPLYFFA Commercial Performance
MIPLYFFA net revenue reached $87.4 million in 2025, underpinning overall sales growth. The product garnered 52 new prescription enrollment forms during the year, totaling 161 since launch, while market access expanded to cover 68% of lives; the European Marketing Authorisation Application remains under review.
3. Operational Updates and Pipeline Progress
Zevra relocated its global headquarters to Boston to leverage specialized talent and hosted a March conference call. Pipeline advances include enrollment of 52 patients in the Phase 3 DiSCOVER trial, initiation of a global expanded access distribution agreement covering 113 patients, and ongoing engagement with regulators to accelerate development.